InsidersTradesSigma
Track the 씨어스 stock price and the full directors' dealings record of the company, a publicly traded company based in South Korea. Shares are listed on the KR market, under the oversight of DART (FSS). Operating in the Health Care sector, 씨어스 has published 13 reports. Market capitalisation: €915.3bn. The latest transaction was disclosed on 10 April 2026 (Purchase). Among the most active insiders: 채정훈. All data is openly available.
6
Insider Decl.
n/a
Thresholds
n/a
6 ops.
Buy Volume
n/a
n/a
Sell Volume
22Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 9,836 of 29,114 companies
59.6
score / 100
Value28
Quality92
FCF yld0.0%
Earn yld1.7%
EV/EBITDA55.4x
ROE92%
Gross mgn72%
Net mgn33%
Debt/EBITDA0.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 10 April 2026
Declarations13 total
Other
Other
Other
Other
Other
Other
Other
13 of 13 declarations
About 씨어스
씨어스 is a company operating in the health and pharmaceutical sector, listed on the XKRX market. It focuses on the development and commercialization of pharmaceutical products.